

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
7 February 2002 (07.02.2002)

PCT

(10) International Publication Number  
**WO 02/09725 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/70, 31/34, 31/20**

(21) International Application Number: **PCT/US00/21046**

(22) International Filing Date: **2 August 2000 (02.08.2000)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(71) Applicant (*for all designated States except US*): **PHARMANUTRIENTS [US/US]; 918 Sherwood Drive, Lake Bluff, IL 60044 (US).**

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **MENARD, Michael [US/US]; 7488 Bittersweet Drive, Gurnee, IL 60031 (US). ROCKWAY, Susie [US/US]; 186 Main Sail Drive, Grayslake, IL 60030 (US).**

(74) Agent: **BARRETT, Robert, M.; Bell, Boyd & Lloyd LLC, P.O. Box 1135, Chicago, IL 60690-1135 (US).**

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF INFLAMMATION, OSTEOARTHRITIS, AND OTHER DEGENERATIVE JOINT DISEASES**

(57) Abstract: Methods and compositions for preventing and/or treating degenerative joint diseases including osteoarthritis as well as inflammation of the joints and for diminishing associated pain are provided. The formulation includes glucosamine, conjugated linoleic acid, and ascorbic acid. Methods of treatment are also provided. The compositions and methods can be provided as an over-the-counter drug, a nutritional supplement, a prescription medication or component thereof, or a functional or medical food or component thereof.

**WO 02/09725 A1**

## SPECIFICATION

### TITLE

**"METHODS AND COMPOSITIONS FOR THE PREVENTION AND  
TREATMENT OF INFLAMMATION, OSTEOARTHRITIS, AND OTHER  
DEGENERATIVE JOINT DISEASES"**

### BACKGROUND OF THE INVENTION

The present invention relates generally to methods of treatment and products for treating disorders. More specifically, the present invention relates to methods and compositions for preventing, treating or providing relief from inflammation of the joints, osteoarthritis, and other degenerative joint diseases, or from pain associated with these conditions.

Inflammation of the joint is a common disorder. One result of such chronic inflammation, osteoarthritis (osteoarthrosis), is a degenerative process that is a major cause of invalidism in the adult population. Osteoarthritis is the most common form of all articular disorders, and first appears asymptotically in the second or third decades and becomes almost universal by age 70. Almost all persons by the age of 40 have some pathological changes in weight bearing joints, although relatively few people are symptomatic. See *Merck Manual*, 16<sup>th</sup> Edition, page 1339.

The etiology of osteoarthritis is unknown. It appears to be the result of a complex system of interacting mechanical, biological, biochemical, and enzymatic feedback loops. When one or more of these systems fails, the clinical events follow. Many mechanisms can initiate the cellular and tissue events that constitute a final common pathway. Such mechanisms include: congenital joint abnormalities; genetic defects; infectious, metabolic, endocrine, and neuropathic diseases; virtually any disease process that alters the normal structure and function of hyaline cartilage; and acute or chronic trauma to the hyaline cartilage or tissue surrounding same. *Merck Manual*, id.

Analgesics and anti-inflammatory agents are used to attempt to manage this disorder. However, they do not stop or slow down the underlying degenerative

process, they only function to relieve the pain. Although such nonsteroidal anti-inflammatory drugs have classically been used to alleviate pain and enhance joint movement associated with osteoarthritis and rheumatoid arthritis, their use is unfortunately associated with accelerated cartilage degeneration. The cartilage  
5 degeneration is due to the pathological effects of IL-1, IL-6, TNF, and PGE<sub>2</sub>, mediators of the acute phase response. The combined effects of these catabolic agents upset the delicate homeostatic balance between synthesis, repair, and degradation of cartilage.

There is a need for improved compositions and methods for treating  
10 degenerative joint disease such as osteoarthritis.

### SUMMARY OF THE INVENTION

Pursuant to the present invention, methods and compositions for preventing and treating degenerative joint diseases including osteoarthritis as well as  
15 inflammation of the joints, as well as associated pain are provided. The formulation includes glucosamine, conjugated linoleic acid, and ascorbic acid. Methods of treatment are also provided. The compositions and methods can be provided as an over-the-counter drug, a nutritional supplement, or a prescription medication or component thereof, or as a component of functional or medical  
20 foods.

To this end the present invention provides a method for preventing or treating degenerative joint disease comprising the step of administering a therapeutically effective amount of a composition comprising conjugated linoleic acid, glucosamine, and ascorbic acid.

25 In an embodiment, approximately 0.5 to about 10.0 grams per day of conjugated linoleic acid are administered.

In an embodiment, approximately 500 mg to about 2500 mg per day of glucosamine is administered. Preferably 1500 mg to 2500 mg per day.

In an embodiment, approximately 50 mg to about 500 mg per day of  
30 ascorbic acid is administered. Preferably 100 mg to 400 mg per day.

In an embodiment, the conjugated linoleic acid is either a pure isomer of octadecadienoic acid, or a mixture of octadecadienoic acid isomers selected from the group consisting of: cis-8, cis-10; cis-8, trans-10; trans-8, cis 10; trans-8, trans-10; cis-9, cis-11; cis-9, trans-11; trans-9, cis-11; trans-9, trans-11; cis-10, cis-12;  
5 cis-9, trans-12; trans-9, cis-12; trans-10, trans-12; cis-11, cis-13; cis-11, trans-13; trans-11, cis-13; trans-11, trans-13 octadecadienoic acid; metabolites thereof, including but not limited to 18:3 cis-6, cis-9, trans-11; 18:3 cis-6, trans-10, cis-12; 18:3 cis-8, trans-12, cis-14; 20:3 cis-8, cis-11, trans-13; 20:4 cis-5, cis-8, cis-11, trans-13; 20:4 cis-5, cis-8, trans-12, cis-14; as well as precursors or derivatives  
10 thereof.

In an embodiment, the composition includes a flavor.

In an embodiment, the composition includes an artificial sweetener.

In an embodiment, the composition is in pill form.

15 In an embodiment, the degenerative joint disease is osteoarthritis.

In an embodiment, the degenerative joint disease is rheumatoid arthritis, or associated disorders.

In a further embodiment of the present invention, a composition is provided comprising a therapeutically effective amount of conjugated linoleic acid, glucosamine, and ascorbic acid.  
20

In an embodiment, the composition comprises approximately 14 % to about 87 % by weight conjugated linoleic acid.

In an embodiment, the composition comprises approximately 12 % to about 82 % by weight glucosamine.

25 In an embodiment, the composition comprises approximately 0.1 % to about 20 % by weight ascorbic acid.

In yet another embodiment of the present invention, a method of treating inflammation of the joints is provided comprising the step of administering a therapeutically effective amount of a composition comprising conjugated linoleic acid, glucosamine, and ascorbic acid.  
30

It is an advantage of the present invention to provide a composition for treating inflammation of the joints.

Another advantage of the present invention is to provide a composition and method for treating osteoarthritis and other degenerative joint diseases.

5 Still further, an advantage of the present invention is to provide a product that can reduce the damaging degenerative process involved in joint disease.

Further, an advantage of the present invention is to provide a product and method that can reverse the damaging degenerative process involved in joint disease.

10 Moreover, an advantage of the present invention is to provide a composition and method for reducing the debilitating pain associated with joint disease.

Furthermore, an advantage of the present invention is to provide a composition and method for increasing mobility in patients with degenerative joint  
15 disease.

A further advantage of the present invention is to provide a composition and method for alleviating the chronic catabolic stress response associated with degenerative joint disease.

20 Still, an advantage of the present invention is to provide a composition and method for reducing inflammatory response associated with joint discomfort.

Additionally, an advantage of the present invention is to provide a composition and method for enhancing cartilage synthesis and/or preventing or minimizing cartilage degradation, thus promoting cartilage repair mechanisms.

25 Additional features and advantages of the present invention will be described in and apparent from the detailed description of the presently preferred embodiments.

**DETAILED DESCRIPTION OF THE  
PRESENTLY PREFERRED EMBODIMENTS**

Pursuant to the present invention, methods and compositions for treating degenerative joint diseases including osteoarthritis as well as inflammation of the joints are provided. The formulation includes glucosamine, conjugated linoleic acid, and ascorbic acid. Methods of treatment are also provided. The composition and method can be provided as an over-the-counter drug, a nutritional supplement, or a prescription medication.

Glucosamine is a component of all human tissue and is found in especially high concentrations in the cartilage. Chemically an aminomonosaccharide, glucosamine provides the building blocks for the O-linked and N-linked glycosaminoglycans comprising the matrix of the connective tissues in the body. The sulfate form is readily absorbed from the small intestine – over 90%. Of the absorbed glucosamine, 25% will be excreted in the urine, 65% excreted as exhaled carbon dioxide, and 10% remaining in the tissues. Once it is taken up into the chondrocytes of cartilage, glucosamine is incorporated into proteoglycans. There have been no reports of significant drug interactions of glucosamine with antibiotics or antidepressants.

Vitamin C is an essential vitamin with an RDI of 60 mg per day. The deficiency of this vitamin is associated with poor wound healing, most likely due to poor collagen synthesis. This water-soluble vitamin is not usually stored, thus, there is little evidence of toxicity.

Current evidence suggests that pro-inflammatory cytokines are responsible for the catabolic process occurring in the pathological tissues. In addition to other catabolic mediators, these pro-inflammatory mediators, particularly interleukins (IL-1, IL-6), and tumor necrosis factor (TNF)- $\alpha$ , are major catabolic compounds involved in the destruction of joint tissues. In the inflammatory response of osteoarthritic articular cells, the changes in cyclooxygenase-2 (COX-2) expression and/or activity seems one of the major determinants for prostaglandin (PGE<sub>2</sub>) production. Chondrocytes are highly sensitive to IL-1 and it appears this cytokine

inhibits repair and regeneration of extracellular matrix and increases catabolic activity of the matrix. Speculation is that immunological mediators (humoral and locally produced) play a primary role in skeletal muscle remodeling and perhaps cartilage remodeling as well. Thus, it appears necessary to modify this catabolic event to retard and/or reverse the breakdown of cartilage.

Conjugated linoleic acid refers to a group of di- and tri-enoic derivatives of linoleic acid that occur naturally in milk and meat of ruminating animals. It can be synthesized in the laboratory and is available commercially as a dietary supplement and has been shown to be nontoxic.

Pursuant to the present invention, conjugated linoleic acid can be conjugated linoleic acid such as that set forth in U.S. Patent No. 5,986,116 the disclosure of which is incorporated herein by reference.

Conjugated linoleic acid appears to modulate the immune system under conditions where COX-2 enzyme is induced by suppressing PGE-2 production.

The mechanism for the observed anti-inflammatory effects of conjugated linoleic acid in various animal models has been associated with reduced arachidonic acid, a precursor for PGE<sub>2</sub>, accumulation in cell membranes. Any effect conjugated linoleic acid has on the synthesis of eicosanoids should correlate with the uptake of conjugated linoleic acid into neutral phospholipids by cells. Conjugated linoleic acid can be readily incorporated in a dose-dependent manner into the tissues of animals consuming diets containing conjugated linoleic acid and a concomitant reduction of arachidonic acid.

Human articular cartilage is highly specialized tissue, composed of chondrocytes embedded in an extracellular matrix. The matrix contains fibrillar components consisting mainly of collagen proteins, and non-fibrillar components, made up of proteoglycans, hyaluronic acid and water. Proteoglycan subunits consist of glycosaminoglycans (chondroitin and keratin sulfates) surrounding a protein core. Cartilage metabolism involves processes of synthesis, repair and degradation, which are ongoing and mediated by chondrocytes. When the balance among these processes is upset as in osteoarthritis and rheumatoid arthritis, cartilage

damage results. The breakdown of the cartilage matrix is believed to be due to locally produced IL-1 from inflammatory cells increasing catabolic activity in adjacent chondrocytes. Thus, CLA may inhibit catabolic response while oral glucosamine stimulates the manufacture of substances necessary for proper joint function and stimulate joint repair.

Orally administered glucosamine sulfate is selectively taken up by the articular cartilage and stimulates the manufacture of glycosaminoglycan, a key structural component of cartilage. It also promotes the incorporation of sulfur into cartilage.

Ascorbic acid acts as a reductive cofactor for post-translational hydroxylation of peptide bound proline and lysine residues during formation of collagen. These hydroxylated amino acids allow cross-linking which stabilizes the triple helical structure of tropocollagen, an essential subunit of procollagen. Ascorbic acid may be involved in gene regulation of collagen synthesis and mRNA processing. In addition, ascorbic acid influences cellular procollagen secretion and biosynthesis of other connective tissue components such as elastin, proteoglycans and bone matrix. Ascorbic acid is also involved with various immune-related functions such as neutrophil chemotaxis, lymphocyte proliferation, antimicrobial and natural killer cell activities and may also modulate prostacyclin, prostaglandins, and B- and T-cell cyclic nucleotides. The mechanisms for these effects are not clearly resolved, nor the absolute amount of ascorbic acid needed to assist in these areas. Because the normal dietary intake of ascorbic acid in humans is often less than 60 mg set as the recommended daily intake (RDI), it appears prudent to add this important cofactor as an active ingredient in this unique formula. Inclusion of this essential vitamin may assist in promoting collagen formation and wound healing.

By way of example and not limitation, examples of the present invention will now be given.

Proposed formulations:

Preferably, the product will comprise as active ingredients:



approximately 14 % to about 87 % by weight conjugated linoleic acid;  
approximately 12 % to about 82 % by weight glucosamine SO<sub>4</sub>; and  
approximately 0.5 % to about 20 % by weight ascorbic acid.

In a preferred embodiment, the product will comprise as active ingredients:

5	conjugated linoleic acid	45%
	glucosamine SO <sub>4</sub>	45%
	ascorbic acid	10%

By way of example, it is envisioned that a dose of the product will  
comprise two tablets of conjugated linoleic acid/glucosamine sulfate/ascorbic acid.

10 Each dose (two tablets) will contain:

conjugated linoleic acid powder	500 mg;
glucosamine SO <sub>4</sub>	500 mg; and
ascorbic acid	100 mg.

The tablets may include the following excipients and flavorings:

15 magnesium stearate, silicone dioxide, croscarmellose sodium, stearic acid,  
microcrystalline cellulose, calcium phosphate, aqueous base film coat.

By way of example and not limitation, contemplative examples of the  
present invention will now be given:

20 Contemplative Example No. 1

To treat osteoarthritis, a daily administration of formulation will be given in an  
amount to provide:

20 mg/kg/day conjugated linoleic acid to 100 mg/kg/day conjugated  
linoleic acid, 1500 mg/day glucosamine to 2500 mg/day glucosamine, and 100  
25 mg/day ascorbic acid to 400 mg/day ascorbic acid .

Contemplative Example No. 2

To treat rheumatoid arthritis, a daily administration of formulation will be  
given in an amount to provide:

20 mg/kg/day conjugated linoleic acid to 100 mg/kg/day conjugated linoleic acid, 1500 mg/day glucosamine to 2500 mg/day glucosamine, and 100 mg/day ascorbic acid to 400 mg/day ascorbic acid .

5

Contemplative Example No. 3

To treat joint discomfort and pain, a daily administration of formulation will be given in an amount to provide:

20 mg/kg/day conjugated linoleic acid to 60 mg/kg/day conjugated linoleic acid, 1500 mg/day glucosamine to 2500 mg/day glucosamine, and 100 mg/day ascorbic acid to 400 mg/day ascorbic acid .

Contemplative Example No. 4 – Prophylactic (maintain joint health)

To maintain joint health a daily administration of formulation will be given in an amount to provide:

20 mg/kg/day conjugated linoleic acid to 60 mg/kg/day conjugated linoleic acid, 1500 mg/day glucosamine to 2500 mg/day glucosamine, and 100 mg/day ascorbic acid to 400 mg/day ascorbic acid.

It should be understood that various changes and modifications to the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the present invention and without diminishing its intended advantages. It is therefore intended that such changes and modifications be covered by the appended claims.

WE CLAIM:

1. A method for treating degenerative joint disease comprising the step of administering a therapeutically effective amount of a composition comprising  
5 conjugated linoleic acid, glucosamine, and ascorbic acid.
2. The method of Claim 1 wherein approximately 0.5 to about 10 grams per day of conjugated linoleic acid are administered.
- 10 3. The method of Claim 1 wherein approximately 1500 mg to about 2500 mg per day of glucosamine is administered.
4. The method of Claim 1 wherein approximately 100 mg to about 400 mg per day of ascorbic acid is administered.
- 15 5. The method of Claim 1 wherein the conjugated linoleic acid is selected from the group consisting of: a pure isomer of octadecadienoic acid; mixtures of octadecadienoic acid isomers: cis-8, cis-10; cis-8, trans-10; trans-8, cis 10; trans-8, trans-10; cis-9, cis-11; cis-9, trans-11; trans-9, cis-11; trans-9, trans-11; cis-10, cis  
20 12; cis-9 trans-12; trans-9, cis-12; trans-10-trans-12; cis-11, cis-13; cis-11, trans-13; trans-11, cis-13; trans-11, trans-13 octadecadienoic acid; 18:3 cis-6, cis-9, trans 11; 18:3 cis-6, trans-10, cis-12; 18:3 cis-8, trans-12, cis-14; 20:3 cis-8, cis-11, trans-13; 20:4 cis-5, cis-8, cis-11, trans-13; 20:4 cis-5, cis-8, trans-12, cis-14; metabolites thereof; and precursors and derivatives thereof.
- 25 6. The method of Claim 1 wherein the composition includes a flavor.
7. The method of Claim 1 wherein the composition includes an artificial sweetener.

30

8. The method of Claim 1 wherein the composition is in pill form.
9. The method of Claim 1 wherein the degenerative joint disease is  
osteoarthritis.
- 5 10. A composition comprising a therapeutically effective amount of  
conjugated linoleic acid, glucosamine, and ascorbic acid.
- 10 11. The composition of Claim 10 wherein approximately 14 % to about  
87 % by weight of the composition is conjugated linoleic acid.
12. The composition of Claim 10 wherein approximately 12 % to about  
82 % by weight of the composition is glucosamine.
- 15 13. The composition of Claim 10 wherein approximately 0.5 % to  
about 20 % by weight of the composition is ascorbic acid.
14. The composition of Claim 10 wherein the conjugated linoleic acid  
is selected from the group consisting of: a pure isomer of octadecadienoic acid;  
20 mixtures of octadecadienoic acid isomers: cis-8, cis-10; cis-8, trans-10; trans-8,  
cis 10; trans-8, trans-10; cis-9, cis-11; cis-9, trans-11; trans-9, cis-11; trans-9, trans-  
11; cis-10, cis 12; cis-9 trans-12; trans-9, cis-12; trans-10-trans-12; cis-11, cis-13;  
cis-11, trans-13; trans-11, cis-13; trans-11, trans-13 octadecadienoic acid; 18:3 cis-  
6, cis-9, trans 11; 18:3 cis-6, trans-10, cis-12; 18:3 cis-8, trans-12, cis-14; 20:3 cis-  
25 8, cis-11, trans-13; 20:4 cis-5, cis-8, cis-11, trans-13; 20:4 cis-5, cis-8, trans-12,  
cis-14; metabolites thereof; and precursors and derivatives thereof.
15. The composition of Claim 10 wherein the composition includes a  
flavor.
- 30

16. The composition of Claim 10 wherein the composition includes an artificial sweetener.

17. The composition of Claim 10 wherein the composition is in pill  
5 form.

18. A method of treating inflammation of the joints comprising the step of administering a therapeutically effective amount of a composition comprising conjugated linoleic acid, glucosamine, and ascorbic acid.  
10

19. The method of Claim 18 wherein approximately 0.5 to about 10 grams per day of conjugated linoleic acid are administered.

20. The method of Claim 18 wherein approximately 1500 mg to about  
15 2500 mg per day of glucosamine is administered.

21. The method of Claim 18 wherein approximately 100 mg to about 400 mg per day of ascorbic acid is administered.

22. The method of Claim 18 wherein the conjugated linoleic acid is selected from the group consisting of: a pure isomer of octadecadienoic acid; mixtures of octadecadienoic acid isomers: cis-8, cis-10; cis-8, trans-10; trans-8, cis 10; trans-8, trans-10; cis-9, cis-11; cis-9, trans-11; trans-9, cis-11; trans-9, trans-11; cis-10, cis 12; cis-9 trans-12; trans-9, cis-12; trans-10-trans-12; cis-11, cis-13;  
25 cis-11, trans-13; trans-11, cis-13; trans-11, trans-13 octadecadienoic acid; 18:3 cis-6, cis-9, trans 11; 18:3 cis-6, trans-10, cis-12; 18:3 cis-8, trans-12, cis-14; 20:3 cis-8, cis-11, trans-13; 20:4 cis-5, cis-8, cis-11, trans-13; 20:4 cis-5, cis-8, trans-12, cis-14; metabolites thereof; and precursors and derivatives thereof.

23. The method of Claim 18 wherein the composition includes a flavor.  
30

24. The method of Claim 18 wherein the composition includes an artificial sweetener.

5           25. The method of Claim 18 wherein the composition is in pill form.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/21046

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) :A61K 31/70, 31/34, 31/20

US CL :514/62, 474, 560,

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/62, 474, 560,

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,603,959 A (HORROBIN et al) 18 February 1997, see particularly claims 7 and 11.	1-25



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"B" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"A" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

23 SEPTEMBER 2000

Date of mailing of the international search report

17 OCT 2000

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

  
WILLIAM JARVIS

Telephone No. (703) 308-1235

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/21046

## B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

BRS WEST (US PATENTS, JPO ABSTRACTS, EPO ABSTRACTS, DWPI)

search terms: linoleic acid, linoleate, octadecadienoic acid, glucosamine, ascorbic acid, joint disease, joint degeneration, joint inflammation, osteoarthritis